**Supplementary Table 1. (A) ACR20 (B) ACR50 (C) ACR70 response rates from Baseline up to Week 24 in the Overall population, and by anti-TNF status.**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **A. ACR20** | **Overall population** | | | | **Anti-TNF-naïve** | | | | **Anti-TNF-IR** | | | | |
| **Weeks** | **Secukinumab  300 mg  with LD**  **(n = 222)** | **Secukinumab  150 mg  with LD**  **(n = 220)** | **Secukinumab  150 mg  without LD  (n = 222)** | **Placebo**  **(n = 332)** | **Secukinumab  300 mg  with LD**  **(n = 154)** | **Secukinumab  150 mg  with LD**  **(n = 158)** | **Secukinumab  150 mg  without LD  (n = 155)** | **Placebo**  **(n = 234)** | **Secukinumab  300 mg  with LD**  **(n = 68)** | **Secukinumab  150 mg  with LD**  **(n = 64)** | **Secukinumab  150 mg  without LD  (n = 65)** | **Placebo**  **(n = 98)** |
| **0** | **0.0** | **0.0** | **0.0** | **0.0** | **0.0** | **0.0** | **0.0** | **0.0** | **0.0** | **0.0** | **0.0** | **0.0** |
| **1** | **16.7** | **11.4** | **11.3** | **6.9** | **18.8** | **12.3** | **12.7** | **8.1** | **11.8** | **9.2** | **7.8** | **4.1** |
| **2** | **31.1** | **26.4** | **25.2** | **14.5** | **32.5** | **26.5** | **26.6** | **15.4** | **27.9** | **26.2** | **21.9** | **12.2** |
| **3** | **44.1** | **35.0** | **31.1** | **19.3** | **48.1** | **36.1** | **33.5** | **21.4** | **35.3** | **32.3** | **25.0** | **14.3** |
| **4** | **47.7** | **42.7** | **40.1** | **20.8** | **50.0** | **45.2** | **44.3** | **24.8** | **42.6** | **36.9** | **29.7** | **11.2** |
| **8** | **59.9** | **52.3** | **45.0** | **24.1** | **62.3** | **58.1** | **48.7** | **27.8** | **54.4** | **38.5** | **35.9** | **15.3** |
| **12** | **58.6** | **52.3** | **54.1** | **27.1** | **61.7** | **54.2** | **61.4** | **30.3** | **51.5** | **47.7** | **35.9** | **19.4** |
| **16** | **62.6** | **55.5** | **59.5** | **27.4** | **67.5** | **57.4** | **67.7** | **31.2** | **51.5** | **50.8** | **39.1** | **18.4** |
| **20** | **63.1** | **54.1** | **54.5** | **26.2** | **67.5** | **57.4** | **62.7** | **31.2** | **52.9** | **46.2** | **34.4** | **14.3** |
| **24** | **63.5** | **53.2** | **53.2** | **23.5** | **68.2** | **57.4** | **62** | **25.6** | **52.9** | **43.1** | **31.3** | **18.4** |

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **B. ACR50** | **Overall population** | | | | **Anti-TNF-naïve** | | | | **Anti-TNF-IR** | | | | |
| **Weeks** | **Secukinumab  300 mg  with LD**  **(n = 222)** | **Secukinumab  150 mg  with LD**  **(n = 220)** | **Secukinumab  150 mg  without LD  (n = 222)** | **Placebo**  **(n = 332)** | **Secukinumab  300 mg  with LD**  **(n = 154)** | **Secukinumab  150 mg  with LD**  **(n = 158)** | **Secukinumab  150 mg  without LD  (n = 155)** | **Placebo**  **(n = 234)** | **Secukinumab  300 mg  with LD**  **(n = 68)** | **Secukinumab  150 mg  with LD**  **(n = 64)** | **Secukinumab  150 mg  without LD  (n = 65)** | **Placebo**  **(n = 98)** |
| **0** | **0.0** | **0.0** | **0.0** | **0.0** | **0.0** | **0.0** | **0.0** | **0.0** | **0.0** | **0.0** | **0.0** | **0.0** |
| **1** | **2.3** | **0.5** | **1.4** | **0.6** | **3.2** | **0.0** | **1.9** | **0.9** | **0.0** | **1.5** | **0.0** | **0.0** |
| **2** | **7.7** | **4.5** | **1.4** | **1.2** | **9.7** | **4.5** | **1.9** | **1.3** | **2.9** | **4.6** | **0.0** | **1.0** |
| **3** | **18.5** | **11.4** | **6.8** | **3.9** | **20.1** | **11.0** | **6.3** | **3.8** | **14.7** | **12.3** | **7.8** | **4.1** |
| **4** | **21.2** | **22.3** | **11.3** | **5.4** | **23.4** | **25.2** | **11.4** | **5.6** | **16.2** | **15.4** | **10.9** | **5.1** |
| **8** | **31.1** | **29.5** | **19.4** | **7.2** | **31.8** | **34.2** | **19.0** | **8.1** | **29.4** | **18.5** | **20.3** | **5.1** |
| **12** | **36.0** | **30.9** | **24.8** | **7.2** | **37.0** | **33.5** | **27.8** | **7.7** | **33.8** | **24.6** | **17.2** | **6.1** |
| **16** | **39.6** | **35.9** | **32.0** | **8.1** | **40.9** | **38.7** | **36.1** | **8.5** | **36.8** | **29.2** | **21.9** | **8.2** |
| **20** | **42.3** | **38.6** | **33.3** | **9.6** | **47.4** | **39.4** | **38** | **10.3** | **30.9** | **36.9** | **21.9** | **8.2** |
| **24** | **43.7** | **39.1** | **36.0** | **8.7** | **47.4** | **44.5** | **41.1** | **8.5** | **35.3** | **26.2** | **23.4** | **9.2** |

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **C. ACR70** | **Overall population** | | | | **Anti-TNF-naïve** | | | | **Anti-TNF-IR** | | | | |
| **Weeks** | **Secukinumab  300 mg  with LD**  **(n = 222)** | **Secukinumab  150 mg  with LD**  **(n = 220)** | **Secukinumab  150 mg  without LD  (n = 222)** | **Placebo**  **(n = 332)** | **Secukinumab  300 mg  with LD**  **(n = 154)** | **Secukinumab  150 mg  with LD**  **(n = 158)** | **Secukinumab  150 mg  without LD  (n = 155)** | **Placebo**  **(n = 234)** | **Secukinumab  300 mg  with LD**  **(n = 68)** | **Secukinumab  150 mg  with LD**  **(n = 64)** | **Secukinumab  150 mg  without LD  (n = 65)** | **Placebo**  **(n = 98)** |
| **0** | **0.0** | **0.0** | **0.0** | **0.0** | **0.0** | **0.0** | **0.0** | **0.0** | **0.0** | **0.0** | **0.0** | **0.0** |
| **1** | **0.0** | **0.0** | **0.5** | **0.0** | **0.0** | **0.0** | **0.6** | **0.0** | **0.0** | **0.0** | **0.0** | **0.0** |
| **2** | **2.3** | **0.5** | **0.0** | **0.0** | **2.6** | **0.6** | **0.0** | **0.0** | **1.5** | **0.0** | **0.0** | **0.0** |
| **3** | **3.6** | **1.8** | **0.5** | **0.6** | **3.9** | **1.9** | **0.0** | **0.4** | **2.9** | **1.5** | **1.6** | **1.0** |
| **4** | **6.3** | **5.0** | **2.7** | **1.5** | **6.5** | **5.8** | **1.9** | **0.9** | **5.9** | **3.1** | **4.7** | **3.1** |
| **8** | **14.4** | **11.4** | **5.4** | **1.8** | **15.6** | **14.8** | **7.0** | **2.1** | **11.8** | **3.1** | **1.6** | **1.0** |
| **12** | **18.9** | **15.0** | **11.7** | **2.7** | **19.5** | **18.1** | **13.3** | **3.0** | **17.6** | **7.7** | **7.8** | **2.0** |
| **16** | **20.3** | **18.2** | **14.9** | **4.2** | **20.1** | **20** | **15.8** | **3.4** | **20.6** | **13.8** | **12.5** | **6.1** |
| **20** | **26.1** | **18.6** | **18.0** | **3.6** | **29.9** | **21.9** | **19.6** | **3.4** | **17.6** | **10.8** | **14.1** | **4.1** |
| **24** | **25.7** | **24.1** | **18.5** | **3.9** | **26.6** | **27.7** | **19.6** | **3.4** | **23.5** | **15.4** | **15.6** | **5.1** |

**Supplementary Table 2. Resolution of enthesitis and dactylitis in the Overall population from Baseline up to Week 24.**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Resolution of enthesitis** | | | | **Resolution of dactylitis** | | | |
| **Weeks** | **Secukinumab  300 mg  with LD**  **(n = 222)** | **Secukinumab  150 mg  with LD**  **(n = 220)** | **Secukinumab  150 mg  without LD  (n = 222)** | **Placebo**  **(n = 332)** | **Secukinumab  300 mg  with LD**  **(n = 154)** | **Secukinumab  150 mg  with LD**  **(n = 158)** | **Secukinumab  150 mg  without LD  (n = 155)** | **Placebo**  **(n = 234)** |
| **0** | **0.0** | **0.0** | **0.0** | **0.0** | **0.0** | **0.0** | **0.0** | **0.0** |
| **1** | **16.4** | **17.0** | **12.4** | **11.5** | **14.6** | **6.2** | **6.8** | **6.5** |
| **2** | **17.1** | **23.4** | **16.3** | **17.7** | **18.3** | **12.5** | **11.7** | **14.5** |
| **3** | **28.6** | **34.8** | **21.7** | **19.8** | **28.0** | **16.2** | **14.6** | **16.1** |
| **4** | **36.4** | **33.3** | **26.4** | **24.5** | **32.9** | **28.7** | **20.4** | **20.2** |
| **8** | **46.4** | **45.4** | **33.3** | **28.1** | **50.0** | **40.0** | **37.9** | **28.2** |
| **12** | **54.3** | **53.2** | **41.1** | **30.7** | **58.5** | **51.2** | **43.7** | **31.5** |
| **16** | **55.7** | **54.6** | **41.9** | **35.4** | **65.9** | **57.5** | **56.3** | **32.3** |
| **24** | **61.4** | **54.6** | **47.3** | **34.4** | **63.4** | **63.7** | **61.2** | **33.9** |